Valeant Pharmaceuticals International reported growth in revenues for its fourth quarter and full year for fiscal 2014.
For the quarter (end-December 31), the company had revenues of $2.3 billion, an increase of 10% from $2.1 billion compared with the same period last year. For the year, the company reported total revenues of $8.3 billion, an increase of 43% from $5.8 billion from 2013.
Fourth-quarter revenues from its dental business grew 38%, from $29.8 million to $41.1 million, compared with the same period last year. For the full year, total revenues for the dental business grew to $123.4 million, an increase of 13% from $109.6 million, compared with the previous year.
"Valeant's relentless focus on building diversified, durable businesses with strong organic growth platforms, coupled with disciplined business development, is paying off for all of our stakeholders," said J. Michael Pearson, chairman and CEO, in press release.
In 2012, Valeant purchased dental pharmaceutical firm OraPharma and also an in-office teeth-whitening business from Klox Technologies.
